Scancell, the Nottingham based cancer vaccine developer, announced that a European composition of matter patent has been granted for SCIB1, the company's lead vaccine. SCIB1 is being developed for the treatment of melanoma and is currently in phase I clinical trials.
The SCLP share price has decreased by 41% over the last year.
Scancell Holdings Plc is currently graded c by LCF Research. To learn more, follow the link.
